Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Share-based Compensation (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Share-based Compensation for 15 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 1.48% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, up 5.09% year-over-year, with the annual reading at $4.3 million for FY2025, 97.75% up from the prior year.
  • Share-based Compensation hit $1.1 million in Q4 2025 for Vistagen Therapeutics, roughly flat from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q1 2022 to a low of $490200.0 in Q1 2021.
  • Historically, Share-based Compensation has averaged $845570.0 across 5 years, with a median of $840250.0 in 2021.
  • Biggest five-year swings in Share-based Compensation: soared 186.01% in 2022 and later crashed 57.13% in 2023.
  • Year by year, Share-based Compensation stood at $723800.0 in 2021, then grew by 3.11% to $746300.0 in 2022, then tumbled by 32.11% to $506700.0 in 2023, then skyrocketed by 113.14% to $1.1 million in 2024, then increased by 1.48% to $1.1 million in 2025.
  • Business Quant data shows Share-based Compensation for VTGN at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $916000.0 in Q2 2025.